Boehringer Ingelheim's Ofev caps now available

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals on Monday announced that Ofev (nintedanib) capsules are now available in the United States. Ofev was approved by the Food and Drug Administration on Oct. 15 to treat idiopathic pulmonary fibrosis. IPF is a condition in which the lungs scar over time. As a result of the scarring, patients with IPF experience shortness of breath, cough and have trouble taking part in physical activities. The disease is rare, fatal and affects nearly 132,000 Americans, according to the company.

 

To support the launch of Ofev, Boehringer Ingelheim established Open Doors, a patient support program that provides financial and nursing support services. One of the goals of Open Doors is to help patients who are prescribed the medicine gain rapid, affordable access to it. 

 

“We are proud to be able to offer IPF patients an effective therapy for this rare and fatal disease, together with comprehensive programs and services to support patients and healthcare providers as they begin therapy with Ofev,” said Tunde Otulana, M.D., a pulmonologist and SVP, clinical development and medical affairs at Boehringer Ingelheim. “Bringing a new treatment such as Ofev to patients when there is such significant unmet need is the result of many years of research and demonstrates our commitment to making a difference for patients with respiratory diseases.”

 

Ofev is available through specialty pharmacy distrubutors as well a select network of pharmacies.